High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) plays a vital
role in treating high-risked or relapsed/refractory lymphoma. Our previous study showed
chidamide combined with cladribine, gemcitabine, and busulfan (ChiCGB) as conditioning
therapy improved the survival of these patients. So we designed this trial to verify if
ChiCGB were better than BCNU, etoposide, cytarabine, and melphalan (BEAM). Patients with
diffuse large B cell or extra-nodal NK/T cell Lymphoma who consent to this study will be
radomized into the trial group who receive ChiCGB or the control group whom receive BEAM.
Patients will be followed for up to 2 years from the HCT.